Prothena Corporation plc Company Name:
PRTA Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 million Advanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer’s disease, into a Phas...
DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022...
PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ: PRTA), a late-stage clinic...